MA51738A - Composés pour le traitement de la douleur - Google Patents
Composés pour le traitement de la douleurInfo
- Publication number
- MA51738A MA51738A MA051738A MA51738A MA51738A MA 51738 A MA51738 A MA 51738A MA 051738 A MA051738 A MA 051738A MA 51738 A MA51738 A MA 51738A MA 51738 A MA51738 A MA 51738A
- Authority
- MA
- Morocco
- Prior art keywords
- pain
- compounds
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/26—Benzomorphans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862626499P | 2018-02-05 | 2018-02-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51738A true MA51738A (fr) | 2021-05-12 |
Family
ID=65444375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051738A MA51738A (fr) | 2018-02-05 | 2019-02-04 | Composés pour le traitement de la douleur |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10604489B2 (fr) |
| EP (1) | EP3749667A1 (fr) |
| JP (1) | JP2021512952A (fr) |
| KR (1) | KR20200136384A (fr) |
| CN (1) | CN111989327A (fr) |
| AU (1) | AU2019216522A1 (fr) |
| BR (1) | BR112020015712A2 (fr) |
| CA (1) | CA3090385A1 (fr) |
| EA (1) | EA202091881A1 (fr) |
| IL (1) | IL276482A (fr) |
| MA (1) | MA51738A (fr) |
| MX (1) | MX2020008195A (fr) |
| SG (1) | SG11202007422QA (fr) |
| WO (1) | WO2019152946A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202007422QA (en) * | 2018-02-05 | 2020-09-29 | Alkermes Inc | Compounds for the treatment of pain |
| WO2021026375A1 (fr) * | 2019-08-07 | 2021-02-11 | Alkermes, Inc. | Composés bicycliques fusionnés pour le traitement de la douleur |
| WO2021026378A1 (fr) * | 2019-08-07 | 2021-02-11 | Alkermes, Inc. | Composés d'indole pour le traitement de la douleur |
| WO2021026377A1 (fr) * | 2019-08-07 | 2021-02-11 | Alkermes, Inc. | Composés contenant du lactame pour le traitement de la douleur |
| WO2021026380A1 (fr) * | 2019-08-07 | 2021-02-11 | Alkermes, Inc. | Composés de phényltriazole pour le traitement de la douleur |
| TW202142537A (zh) | 2020-02-04 | 2021-11-16 | 美商艾爾凱默斯公司 | ３－（（１Ｒ，５Ｓ，９ｒ）－９－乙氧基－３－氮雜雙環并［３．３．１］壬烷－９－基）—苯甲醯胺之結晶形式及其鹽形式 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3167562A (en) | 1965-01-26 | New j-azabicyclo | ||
| GB952137A (en) | 1961-03-14 | 1964-03-11 | Sankyo Co | New 3-azabicyclo [3.3.1] nonane compounds and a process for preparing these compounds |
| US3196154A (en) | 1962-05-17 | 1965-07-20 | Sterling Drug Inc | 3-substituted-9-methyl-3, 9-diazabicyclo [3.3.1] nonanes |
| US3475439A (en) | 1966-05-07 | 1969-10-28 | Sankyo Co | 3-azabicyclo(3.3.1)nonane compounds |
| GB1195746A (en) | 1967-06-07 | 1970-06-24 | Yoshitomi Pharmaceutical | 3-Azabicyclo [3,3,1] Nonane Derivatives |
| GB1393253A (en) | 1971-09-10 | 1975-05-07 | Wyeth John & Brother Ltd | 3-azabicyclo-3,3,1-nonanes |
| JPS4856680A (fr) | 1971-11-18 | 1973-08-09 | ||
| JPS4961168A (fr) | 1972-10-14 | 1974-06-13 | ||
| JPS5592384A (en) * | 1978-12-30 | 1980-07-12 | Beecham Group Ltd | Compound having pharmacological activity |
| IL59004A0 (en) * | 1978-12-30 | 1980-03-31 | Beecham Group Ltd | Substituted benzamides their preparation and pharmaceutical compositions containing them |
| ES2098357T3 (es) | 1990-06-05 | 1997-05-01 | Toray Industries | Derivado de indol. |
| EP0483403A1 (fr) | 1990-10-31 | 1992-05-06 | Hoechst Aktiengesellschaft | Dérivés d'amino-acides ayant une activité d'inhibitrice de rénine, leur procédé de préparation et les médicaments les contenant |
| DE4341403A1 (de) | 1993-12-04 | 1995-06-08 | Basf Ag | N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung |
| US5541217A (en) | 1995-05-17 | 1996-07-30 | Ortho Pharmaceutical Corporation | 4-arylcyclopenta[c]pyrrole analgesics |
| JP2808089B2 (ja) | 1995-08-29 | 1998-10-08 | レーザーテクノ株式会社 | 墨出し用レーザー装置 |
| TWI244481B (en) | 1998-12-23 | 2005-12-01 | Pfizer | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| DE19952146A1 (de) | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| EP1480977A2 (fr) * | 2002-02-15 | 2004-12-01 | PHARMACIA & UPJOHN COMPANY | Composes aryle substitues permettant de traiter une maladie |
| US7056930B2 (en) | 2003-04-14 | 2006-06-06 | Pfizer Inc. | 2-Azabicyclo[3.3.1]nonane derivatives |
| EP1615894A2 (fr) * | 2003-04-14 | 2006-01-18 | Pfizer Products Inc. | Derives de 3-azabicyclo 3.2.1]octane |
| US20050043327A1 (en) * | 2003-08-21 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| WO2005037832A2 (fr) | 2003-10-15 | 2005-04-28 | Targacept, Inc. | Compositions pharmaceutiques et methodes destinees au soulagement de la douleur et au traitement de troubles du systeme nerveux central |
| MX2007000015A (es) | 2004-06-22 | 2007-03-07 | Schering Corp | Ligandos de receptor de canabinoide. |
| WO2007029156A2 (fr) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Derives d'isoindoledione comme antagonistes de recepteurs adrenergiques |
| US7538110B2 (en) | 2005-10-27 | 2009-05-26 | Adolor Corporation | Opioid antagonists |
| WO2007056086A2 (fr) | 2005-11-03 | 2007-05-18 | Activbiotics, Incorporated | Analogues de la rifamycine et leurs utilisations |
| MY145633A (en) | 2006-03-01 | 2012-03-15 | Theravance Inc | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| FR2918986B1 (fr) | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| TWI423801B (zh) | 2007-08-27 | 2014-01-21 | Theravance Inc | 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物 |
| US8048895B2 (en) | 2008-04-18 | 2011-11-01 | Research Triangle Institute | Kappa opioid receptor ligands |
| GB0815947D0 (en) | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
| US8759357B2 (en) | 2009-10-08 | 2014-06-24 | Merck Sharp & Dohme Corp. | Inhibitors of fatty acid binding protein (FABP) |
| FR2953839A1 (fr) | 2009-12-14 | 2011-06-17 | Sanofi Aventis | Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75 |
| TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
| ES2577829T3 (es) | 2010-06-04 | 2016-07-19 | F. Hoffmann-La Roche Ag | Derivados de aminopirimidina como moduladores de la LRRK2 |
| WO2012075232A1 (fr) | 2010-12-04 | 2012-06-07 | Trevena, Inc. | Ligands de récepteurs opioïdes et procédés d'utilisation et de fabrication de ceux-ci |
| SI2688403T1 (sl) | 2011-03-23 | 2017-08-31 | Trevena, Inc. | Ligandi opioidnih receptorjev in metode uporabe in izdelave istega |
| JP2014237589A (ja) | 2011-09-28 | 2014-12-18 | 日本曹達株式会社 | 環状アミン化合物および有害生物防除剤 |
| GB2498976A (en) | 2012-02-01 | 2013-08-07 | Prosidion Ltd | GPR119 agonists useful in the treatment of type II diabetes |
| JP2015083543A (ja) | 2012-02-14 | 2015-04-30 | 大日本住友製薬株式会社 | 新規縮環ピロリジン誘導体 |
| EP2716291B1 (fr) * | 2012-10-08 | 2019-11-27 | Universität Ulm | Combinaison d'opioïdes et médicaments anticancéreux pour le traitement du cancer |
| WO2014194519A1 (fr) | 2013-06-07 | 2014-12-11 | Merck Sharp & Dohme Corp. | Dérivés imidazole et leurs procédés d'utilisation pour l'amélioration des propriétés pharmacocinétiques d'un médicament |
| WO2015091931A1 (fr) | 2013-12-20 | 2015-06-25 | AbbVie Deutschland GmbH & Co. KG | Dérivés d'oxindole à substituant azétidinyl substitué par pipéridyl, et leur utilisation pour le traitement de maladies liées à la vasopressine |
| NO2721710T3 (fr) | 2014-08-21 | 2018-03-31 | ||
| ES2896487T3 (es) | 2016-09-01 | 2022-02-24 | Mebias Discovery Llc | Derivados de urea sustituidos para el tratamiento del dolor |
| KR102603671B1 (ko) | 2017-01-17 | 2023-11-17 | 메비아스 디스커버리 인코포레이티드 | 치환된 3-디알킬아미노메틸-피페리딘-4-일-벤즈아미드 및 이를 제조 및 사용하는 방법 |
| SG11202007422QA (en) * | 2018-02-05 | 2020-09-29 | Alkermes Inc | Compounds for the treatment of pain |
-
2019
- 2019-02-04 SG SG11202007422QA patent/SG11202007422QA/en unknown
- 2019-02-04 CN CN201980021811.0A patent/CN111989327A/zh active Pending
- 2019-02-04 KR KR1020207025543A patent/KR20200136384A/ko not_active Ceased
- 2019-02-04 WO PCT/US2019/016543 patent/WO2019152946A1/fr not_active Ceased
- 2019-02-04 US US16/267,025 patent/US10604489B2/en active Active
- 2019-02-04 JP JP2020564036A patent/JP2021512952A/ja active Pending
- 2019-02-04 EA EA202091881A patent/EA202091881A1/ru unknown
- 2019-02-04 AU AU2019216522A patent/AU2019216522A1/en not_active Abandoned
- 2019-02-04 MA MA051738A patent/MA51738A/fr unknown
- 2019-02-04 MX MX2020008195A patent/MX2020008195A/es unknown
- 2019-02-04 BR BR112020015712-0A patent/BR112020015712A2/pt not_active Application Discontinuation
- 2019-02-04 EP EP19705893.6A patent/EP3749667A1/fr not_active Withdrawn
- 2019-02-04 CA CA3090385A patent/CA3090385A1/fr active Pending
-
2020
- 2020-02-13 US US16/790,224 patent/US11180455B2/en not_active Expired - Fee Related
- 2020-08-04 IL IL276482A patent/IL276482A/en unknown
-
2021
- 2021-10-12 US US17/499,686 patent/US20220033394A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020015712A2 (pt) | 2020-12-08 |
| IL276482A (en) | 2020-09-30 |
| US11180455B2 (en) | 2021-11-23 |
| JP2021512952A (ja) | 2021-05-20 |
| CN111989327A (zh) | 2020-11-24 |
| US10604489B2 (en) | 2020-03-31 |
| WO2019152946A1 (fr) | 2019-08-08 |
| US20200255383A1 (en) | 2020-08-13 |
| US20190241524A1 (en) | 2019-08-08 |
| EP3749667A1 (fr) | 2020-12-16 |
| KR20200136384A (ko) | 2020-12-07 |
| EA202091881A1 (ru) | 2020-11-10 |
| US20220033394A1 (en) | 2022-02-03 |
| CA3090385A1 (fr) | 2019-08-08 |
| MX2020008195A (es) | 2020-11-24 |
| SG11202007422QA (en) | 2020-09-29 |
| AU2019216522A1 (en) | 2020-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3935050A4 (fr) | Composés hétérocycliques pour traitement médical | |
| EP3893940A4 (fr) | Polythérapie pour le traitement de la dystrophie musculaire | |
| EP3728271A4 (fr) | Composés macrocycliques pour le traitement de maladie | |
| EP3968996A4 (fr) | Composés triaryles pour le traitement de maladies pd-l1 | |
| MA55325A (fr) | Composés pour le traitement de maladies pd-l1 | |
| EP3704108A4 (fr) | Composés et compositions pour le traitement de troubles hématologiques | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA44083A (fr) | Composés de biarylmonobactame pour le traitement d'infections bactériennes | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| EP3621973A4 (fr) | Composés pour la prévention et le traitement de maladies et leur utilisation | |
| EP3852745A4 (fr) | Composés destinés au traitement de certaines leucémies | |
| EP3883554A4 (fr) | Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance | |
| EP3317274A4 (fr) | Utilisation de composés de chloroquine et de clémizole pour le traitement d'états pathologiques inflammatoires et cancéreux | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| EP3352749A4 (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| EP3883553A4 (fr) | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau | |
| MA51672A (fr) | Composés destinés au traitement des troubles kinases-dépendants | |
| EP3773221A4 (fr) | Traitement pour l'hydrocéphalie | |
| EP3898991A4 (fr) | Administration périnéale de résinifératoxine pour le traitement de la douleur maladaptative | |
| EP3805216A4 (fr) | Composés pour le traitement ou la prévention de maladies hépatiques | |
| MA49140A (fr) | Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques | |
| EP3877382A4 (fr) | Nouveaux composés pour le traitement de maladies respiratoires | |
| EP3373931A4 (fr) | Composés hétérocycliques pour le traitement de maladies | |
| EP3413898A4 (fr) | Utilisation de tréhalose pour le traitement de maladies neurologiques | |
| MA55141A (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau |